H E A LT H C A R E - A S S O C I AT E D

I N F E C T I O N S

Your challenge. Our commitment.

from diagnosis, the seeds of better health

HAI : A Critical Public Health Issue

Healthcare-associated infections (HAI) continue to be a major cause of morbidity, mortality and excess healthcare cost.
HAI Facts and Figures USA: Up to 2 million healthcare-associated infections (HAI) per year - 80,000 of them are lethal or may contribute to death - and generate US$ 4.5 to 5.7 billion additional expenses per year (WHO figures, 2005). Europe: 5 million HAI per year. 50,000 (1%) are lethal and contribute to death in 135,000 cases (2.7%) (Suetens C, IPSE, 2006). HAI concern 5 to 15% of patients in an acute-care hospital (15-50% in ICUs). At any time, 1.4 million people are suffering from HAI (WHO figures, 2005). Hospitals, critical care facilities, surgical centers, long-term care institutions, ambulatory care whatever the healthcare setting HAI is now recognized worldwide as a major public health issue. The implementation of infection control programs, including dedicated committees, patient screening, reinforced hygiene measures, nursing protocols and antibiotic stewardship, has already been shown to be effective in reducing the number of healthcare-associated infections. Between 20 and 30% of HAI are considered to be preventable. Reducing HAI through infection control programs In the Netherlands, the Search and Destroy strategy has enabled the S. aureus resistance rate to be maintained at <0.5%. Systematic screening reduces MRSA rate by 50% (Harbarth S, 2000). A 60,000 program enables 8 M savings through HAI reduction of 6-9% (Durand-Zaleski I, 2001). Pre-emptive isolation plus Active Surveillance Culture decreases VRE transmission by 65% (Perencevitch EN, 2004). Nevertheless, current facts and figures reflect the essence of the challenge ahead : despite all the efforts made, HAI will remain a permanent threat and a major concern for all healthcare providers. There are many reasons for this : Patient conditions (highly premature newborns,
increasingly aged populations, immunocompromized persons) and comorbid diseases make hospita-

lized patients more susceptible to opportunistic infections. More invasive investigations and sophisticated techniques together with more aggressive treatments increase the risk of HAI.

Extensive use of antibiotics has led to the development of multidrug resistant bacteria, limiting the action of drugs previously considered to be highly active. Up to 70% of organisms involved in HAI are resistant to at least one antibiotic (CDC figures, 2006).

Microbiology is Key in the Fight against HAI

Whether viruses, bacteria, parasites or fungi, recent history has highlighted how fast microorganisms develop, adapt and change.

Microbes : the more you know, the harder you can hit them !
Advanced knowledge of microorganisms is crucial to fight back and bring them under control: this is the very essence of microbiology. Experience and expertise in this field can help keep pace with the numerous and rapid evolutions of organisms, and lead to more proactive solutions. The contribution of microbiology is therefore essential at each step of the fight against HAI:

Prevention, Surveillance, Intervention, Diagnosis, Treatment guidance, Corrective actions.

bioMrieux Over 40 years of experience in tracking microbes

1963
Culture Media

1969
API identification strips

1972
Ready-to-use culture media plates

1979
ATB strips for susceptibility testing

1981
First SLIDEX kit for microbial antigen detection

1988
VITEK automated systems for identification and resistance

1989
BacT/ALERT automated blood culture system Chromogenic media

bioMrieux Your Logical Partner in the Fight against HAI

Microbiology lies at the heart of our commitment to the fight against infectious diseases, and is a core competence at bioMrieux. Our major innovations in microbiology have enabled us to develop an expertise that is recognized worldwide. We put this expertise into action for more rapid, reliable diagnosis as well as better adapted and earlier treatments. For more than 4 decades, bioMrieux has been listening to and working closely with microbiology laboratories in order to develop the most adapted solutions to respond to healthcare concerns.

bioMrieuxs Unique Of

bioMrieux covers the complete spectrum of diagnostic tech

bacterial culture, immunoassays, molecular-based technologies, instruments and software developm

Our solutions for prevention, inte respond to the needs of healthc

SURVEILLANCE

Your needs
Identify HAI Detect outbreaks or abnormal events Get alerts on multi-drug resistant or rare organisms Develop statistical studies Monitor antibiotic use

PREVENTION

Your needs
Perform patient screening tests, in particular for Multi-Drug Resistant Organisms (MDRO) Implement environmental controls

Fighting side by side with healthcare professionals against HAI, bioMrieux is dedicated to delivering relevant microbiology solutions to empower clinical decisions.

INTERVENTION

Your needs
Diagnose HAI Detect and monitor outbreaks Investigate infection source and reservoir

1991
VIDAS Immunoassay system

1998
Fully automated VITEK 2 system and Advanced Expert System

2002
NucliSENS EasyQ, real-time amplification and detection platform VIGI@act epidemiology software

2005
chromID MRSA screening test

2007
DiversiLab bacterial typing system VIDAS C. difficile A/B chromID ESBL and chromID VRE

ffer in Microbiology
nologies :

ment.

ervention and surveillance care professionals. Our solutions

VIGI@act: epidemiology software providing
- continuous surveillance - real-time alerts - local statistics

STELLARA: antibiotic therapy monitoring software

Our solutions
chromID MRSA, chromID ESBL and chromID VRE
chromogenic culture media for MDRO screening

Environmental monitoring
- Count-Tact: culture media for surface control - airIDEAL 3P: air sampler for effective measurement of aerobiocontamination - Culture media for detection of Legionella and other water contaminants

Together, we can meet the challenges in the fight against HAI by

Reducing or stabilizing the rate of healthcareassociated infections, Decreasing hospital costs And ultimately improving healthcare quality and patient safety

Our solutions
Identification and antimicrobial susceptibility testing
- API strips: the reference in identification - VITEK 2 and Advanced Expert System: automated identification and resistance testing - BacT/ALERT 3D: automated blood culture range - VIDAS: rapid detection of C. difficile toxins A and B, rotavirus - VIKIA Rota-Adeno: rapid detection and identification of rotavirus and adenovirus in stool samples - NucliSENS EasyQ RSV A+B: molecular test for respiratory syncytial virus

Microbial genotyping
- DiversiLab: genotypic characterization of bacteria, yeasts and molds to assist in infection source identification
For availability, please contact your local bioMrieux representative.

03-07 / 002GB99126A / This document is not legally binding. bioMrieux S.A. reserves the right to modify specifications without notice BIOMERIEUX, the blue logo and from diagnosis the seeds of better health, Advanced Expert System, airIDEAL 3P, API, BacT/ALERT, chromID, Count-Tact, DiversiLab, NucliSENS EasyQ, SLIDEX, STELLARA, VIDAS, VIGI@ct, VIKIA, VITEK 2 are used, pending and/or registered trademarks belonging to bioMrieux S.A. or one of its subsidiaries bioMrieux S.A. RCS Lyon 673 620 399 / Photos: bioMrieux, GettyImages, Nol Bouchut / Printed in France / TL. McCANN SANT LYON / RCS Lyon B 398 160 242

www.biomerieux.com

bioMrieux S.A. 69280 Marcy lEtoile France Tel. : 33 (0)4 78 87 20 00 Fax : 33 (0)4 78 87 20 90

Empowering clinical decisions in the fight against HAI

EMPOWERING

CLINICAL DECISIONS